Brief: Immunome Completes Dosing First Cohort Of Patients In Phase 1b Study Of IMM-BCP-01
06/01/2023 13:25
Jan 6 (Reuters) - Immunome Inc IMNM.O :
* IMMUNOME - COMPLETED DOSING OF FIRST COHORT OF PATIENTS IN
PHASE
1B STUDY OF IMM-BCP-01 WITH NO SIGNIFICANT TREATMENT-RELATED
ADVERSE EVENTS
* IMMUNOME INC - HAS DECIDED TO SEEK A PARTNER IN ORDER TO
CONTINUE TRIAL AND FOR ANY FURTHER DEVELOPMENT ACTIVITIES
Further company coverage: IMNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage